Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bintrafusp Alfa in Resectable Biliary Tract Cancer
NCT04727541Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in biliary tract cancer (BTC), sponsored by AIO-Studien. Started Jul 2021; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04727541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727541.